Sufferers dwelling with myelofibrosis who additionally expertise anemia might even see significant enhancements in blood counts when handled with Vonjo (pacritinib), based on new real-world scientific findings which have been introduced on the 13th Annual Society of Hematologic Oncology (SOHO) Congress.
Investigators discovered that the examine, which evaluated hemoglobin (Hb) and platelet (PLT) responses in sufferers with myelofibrosis receiving Vonjo in routine scientific apply, aligned with scientific guideline suggestions for its use in sufferers with anemia.
Anemia is a big complication in myelofibrosis and might have an effect on high quality of life and general well being. Anemia happens when the physique lacks sufficient wholesome crimson blood cells or hemoglobin to ship oxygen to tissues. This could result in fatigue, weak point, and shortness of breath, based on the Mayo Clinic web site, which famous that anemia has many varieties and causes.
Vonjo, a JAK1-sparing inhibitor concentrating on JAK2/IRAK1/ACV1 pathways, has beforehand been proven in scientific trials to cut back the necessity for blood transfusions in sufferers who should not transfusion-dependent. Importantly, Vonjo will be administered at full dosage no matter pre-existing cytopenias, making it a viable possibility for sufferers scuffling with low blood counts.
The examine used the Integra-PrecisionQ database, which incorporates digital well being data and apply administration knowledge from predominantly group oncology practices. Sufferers recognized with myelofibrosis who initiated Vonjo remedy between June 2022 and June 2024 have been included. Solely sufferers with not less than 90 days of follow-up and full laboratory knowledge have been analyzed. Outcomes assessed included Hb response, outlined as a rise of not less than 1.5 g/dL, PLT rely, and modifications in Hb ranges over time. Sufferers have been grouped by baseline Hb ranges: extreme anemia, average anemia, and delicate or no anemia.
Majority of Sufferers Present Hemoglobin Enchancment Inside 90 Days
Amongst 148 sufferers with ample follow-up, 44% achieved a hemoglobin response, and 75% of those responders reached the goal inside 90 days. Sufferers with early Hb responses had average or extreme anemia at baseline. The median age of sufferers with a 90-day Hb response (49 sufferers) was 76 years, and 55.1% have been male. Race distribution included White (59.1%), Black or African American (4.2%), and Asian (2.0%).
Anemia severity at index included extreme anemia in 61.2% of sufferers, average anemia in 22.4%, and delicate or no anemia in 16.3%. Median time from myelofibrosis analysis to Vonjo initiation was 11.4 months, and median follow-up was 10 months. Amongst sufferers with not less than 9 months of follow-up, median Vonjo therapy length was 5.2 months.
Median time to Hb response was 40 days amongst all responders (65 sufferers) and 33 days amongst sufferers attaining a 90-day response. Relating to line of remedy, 26.5% acquired Vonjo as first-line therapy, 44.9% as second-line, and 30.6% as third-line or later. Some sufferers acquired Vonjo throughout a number of traces of remedy.
Vonjo Helps Platelet Stability Throughout Therapy
Along with enhancements in hemoglobin, platelet counts remained steady via six months of Vonjo remedy. Sufferers with average or delicate/no anemia skilled modest enhancements in PLT counts at day 90, whereas these with extreme anemia maintained steady counts via day 180. This stability is especially essential for sufferers vulnerable to bleeding or different problems related to low platelet counts, emphasizing Vonjo’s potential function in supporting general hematologic well being in myelofibrosis.
“Sufferers with myelofibrosis and anemia handled with Vonjo in real-world scientific settings demonstrated enhancements in hemoglobin ranges and platelet counts,” examine investigators concluded of their poster, including that “These real-world findings align with the rule suggestions for the usage of PAC in sufferers with anemia.”
Reference
- Hematologic Response in Sufferers With Myelofibrosis Handled With Pacritinib in Actual-World Medical Settings, by Dr. Raajit Okay Rampal, et al. Offered at: thirteenth Society of Hematologic Oncology (SOHO) Congress; September 3-6, 2025; Houston, Texas. Summary MPN-1038.
- “Anemia: Signs and Causes,” by Mayo Clinic. https://www.mayoclinic.org/diseases-conditions/anemia/symptoms-causes/syc-20351360
For extra information on most cancers updates, analysis and schooling,
